Actuate Therapeutics, Inc. has recently disclosed a major stock transaction involving its President and CEO, Daniel M. Schmitt. The transaction, which took place on October 28, 2026, is noteworthy as it reflects the company's ongoing activities and commitment to its growth in the pharmaceutical preparations sector.

In the latest SEC filing, Schmitt reported acquiring 140,844 shares of common stock at a price of $0.355 per share. Following this transaction, he now holds a total of 442,560 shares directly. Additionally, Schmitt is associated with several irrevocable trusts that collectively own 66,689 shares, further indicating his significant stake in the company.

Background

Actuate Therapeutics, Inc. operates under the SIC classification of 2834, which pertains to Pharmaceutical Preparations. The company is publicly traded on the Nasdaq under the ticker symbol ACTU. Established as an emerging growth company, Actuate focuses on developing innovative therapies to address unmet medical needs.

What the Filing Says

The recent filing details Schmitt's acquisition of shares, stating, "Represents shares of common stock purchased on October 28, 2026 in connection with Issuer's public offering." This indicates that the transaction is part of a broader initiative to raise capital for the company.

Impact

This transaction may affect various stakeholders, including investors, employees, and industry analysts. Schmitt's increased ownership stake may signal confidence in the company's future prospects, potentially influencing investor sentiment. Additionally, other companies in the pharmaceutical preparations sector may observe this activity as they strategize their own market positions.

What's Next

The filing does not say what happens next.